Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

blank

 

Recent News and Articles on the Keywords: celgene's revlimid + revlimid + myeloma  Related to the article below (Last Update: 5/13/2008)


RTT News
Celgene's Sales Show Some Upside
Barron's - May 9, 2008
Prescription growth was 10% for Revlimid in the multiple myeloma (MM) setting, while it was relatively flat in the Myelodysplastic Syndrome (MDS) setting. ...
UPDATE 1-Celgene posts net loss on Pharmion acquisition Reuters
Celgene swings to first-quarter loss, hurt by R&D costs Forbes
Winners & Losers Health Winners & Losers: Barr TheStreet.com
all 21 news articles »  CELG - BRL
Celgene Corp. Q1 2008 Earnings Call Transcript
Seeking Alpha, NY - May 8, 2008
REVLIMID was also granted marketing approval for multiple myeloma in Australia. It is our goal to attain government reimbursement in both of these markets ...CELG
Cancer Drug Maker Sees Growth Potential In Europe And Beyond
CNNMoney.com - Apr 16, 2008
New Jersey-based Celgene's blockbuster drug Revlimid treats a cancer called multiple myeloma, which attacks blood and bones. The median survival time is 2.9 ...MLNM
Celgene posts net loss on Pharmion acquisition
Business Spectator, Australia - May 8, 2008
Revlimid net sales nearly doubled to $US286.8 million. Revlimid is the successor to Celgene's multiple myeloma drug Thalomid. Celgene forecast full-year ...CELG
Celgene remains a top-tier biopharmaceutical
BloggingStocks - Apr 29, 2008
The risks: Slower-than-expected sales increases for Revlimid would obviously hurt Celgene's results. Analysts are also keeping an eye on CELG's core ...CELG
Current and Emerging Drugs Have Not Yet Shown an Advantage in ...
Earthtimes (press release), UK - May 8, 2008
... the multiple myeloma market sales-leader, the clinical gold standard treatment for relapsed disease is lenalidomide/dexamethasone (Celgene's Revlimid, ...
Garden State Briefs
The Star-Ledger - NJ.com, NJ - Apr 21, 2008
Celgene won European approval last year of its lead drug, Revlimid, as a treatment for patients who have failed an initial round of multiple myeloma therapy ...
Source: Google News

[CITATION] … with Doxorubicin and Dexamethasone (RAD) in Patients with Relapsed or Refractory Multiple Myeloma.
C Gerecke, S Knop, MS Topp, S Kotkiewitz, H … - Blood, 2005 - 2005, The American Society of Hematology

Thalidomide as a novel therapeutic agent: new uses for an old product -
SK Teo, DI Stirling, JB Zeldis - Drug Discovery Today, 2005 - Elsevier
... physicians must be registered in Celgene's database ... yet to be approved for multiple
myeloma in the ... the more-potent IMID?s, particularly lenalidomide, where the ...

Billion dollar babies?biotech drugs as blockbusters -
S Lawrence - Nature Biotechnology, 2007 - nature.com
... Avastin and Summit, New Jersey?based Celgene's, Revlimid (lenalidomide). ... triple sales
and Revlimid, an analog ... abnormality and multiple myeloma, could become ...

Celgene's multiple myeloma drug lenalidomide [Revlimid] is forecast to produce sales generating$ …
RL Pharmanewsfeed - PharmacoEconomics & Outcomes News, 2005 - pecnews.adisonline.com
... Celgene's multiple myeloma drug lenalidomide [Revlimid] is forecast to produce
sales generating $US321 million in 2009,. [Media release]. ...

Pipeline Insight: Hematological malignancies-Targeted treatments & immunotherapy -
C LeadDiscovery, GSK Nelarabine, CT Pixantrone - leaddiscovery.co.uk
... 85% response rate in newly diagnosed multiple myeloma patients - page 114; Celgene
anticipate initiating a Phase III trial examining Revlimid in MDS - page 115; ...
-

A turbulent year at the agency -
M Ratner - Nature Biotechnology, 2006 - nature.com
... Celgene's (Summit, NJ, USA) Revlimid (lenalidomide), a niche cancer drug for
myelodysplastic syndrome and multiple myeloma that could reach half-a-billion ...

News in brief
C swallows Pharmion - Nature Biotechnology, 2008 - nature.com
... Although Celgene had recently increased sales of Revlimid (lenalidomide), a thalidomide ...
Velcade (bortezomid) performed well in multiple myeloma disorders ...

METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT AND MANAGEMENT OF CANCERS … -
JB Zeldis - EP Patent 1,505,973, 2005 - freepatentsonline.com
... DATABASE PHARMAML ?Online? "Celgene's Revimid an orphan ... 10-09), DATABASE NLDB ?Online?
"Celgene drug promises ... and refractory multiple myeloma (MM)" BLOOD ...

[CITATION] Lenalidomide Has Activity in a Phase II Trial in Patients with Primary Systemic Amyloidosis.
A Dispenzieri, MQ Lacy, SR Zeldenrust, SM Geyer, … - Blood, 2005 - 2005, The American Society of Hematology

Methods for treatment and management of brain cancer using 1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4- … -
JB Zeldis - US Patent 7,323,479, 2008 - freepatentsonline.com
... Celgene Corporation, ?Revlimid? receives orphan drug designation from the European
commission for multiple myeloma,? Press Release, Feb. 2004. ...

Source: Google Scholar

Celgene's Revlimid delays myeloma progression

Last Updated: 2007-12-10 13:00:53 -0400 (Reuters Health)

BOSTON - Celgene Corp said on Sunday that its cancer drug Revlimid in combination with the steroid dexamethasone helped newly diagnosed patients with multiple myeloma stave off their disease longer than those who took dexamethasone alone.

Data from a trial conducted by the Southwest Oncology Group (SWOG) and presented at the annual meeting of the American Society of Hematology showed a 93 percent survival rate at one year in the Revlimid plus dexamethasone arm and a 91 percent survival rate in the dexamethasone only arm.

The lack of real difference between the two arms was a function of the trial design, under which if a patient in the dexamethasone arm relapsed, the patient was given Revlimid.

The SWOG trial closed early in May after preliminary one-year survival results from a separate trial conducted by the Eastern Cooperative Oncology Group (ECOG) showed a greater survival advantage for patients taking Revlimid plus a low dose of dexamethasone compared to those taking a higher dose of dexamethasone.

The SWOG trial showed that 77 percent of patients in the Revlimid plus dexamethasone group were still in remission and alive at one year.

In the dexamethasone alone group, it was 55 percent.

The takeaway from the two trials, investigators say, is that Revlimid plus low-dose dexamethasone is the ideal combination.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 

 

China market may breed deadly viruses

Last Updated: 2007-12-10 11:01:00 -0400 (Reuters Health)

GUANGZHOU, China - Scorpions scamper in bowls, water snakes coil in tanks and cats whine in cramped cages, waiting to be slaughtered, skinned and served for dinner.

Welcome to the Qingping market in the southern Chinese city of Guangzhou, where everything from turtles to insects is sold alongside fowl and freshly caught fish.An outbreak of the SARS virus in 2002 resulted in a local gourmet favorite -- the civet -- being banished to the black market. The raccoon-like animal was blamed for spreading SARS, which infected 8,000 people globally and killed 800.But exotic wildlife and squalor have returned to the Qingping market, making health officials worried that another killer virus could emerge."We face similar threats from other viruses and such epidemics can happen because we continue to have very crowded markets in China," said Lo Wing-lok, an infectious disease expert in Hong Kong."Even though official measures are in place, they are not faithfully followed. We are not talking about just civet cats, but all animals," he added.Ever since Severe Respiratory Disease Syndrome (SARS) virus emerged in China, authorities have fought to rectify the country's image and clean up its market.Civets, which are a delicacy in southern China, are now banned for sale and consumption, and a nine-storey traditional medicine plaza has replaced Qingping's wild animal market."The market is much different now," said He Zhiquan, an official from Guangdong's foreign affairs office."Civet cats are forbidden, and sanitation is an important issue. Most live animals are sold on the city's outskirts. You can see it's more of a normal market now."Propaganda posters such as "Everyone should honor the policy of paying attention to product safety", hang everywhere at Qingping.Still, sights abound that would send even the most ardent carnivores running.In a dark shop near the new medicine mall, feces and urine drip like goo thorough stacked cages of squawking chickens and meowing cats."The Qingping market is dirty," said a Guangzhou-born taxi driver, surnamed Mo. "It's dirty because it's old, and the government is unwilling to put up enough money to fix it."WET FLOORS, HIDDEN BEASTSIn wealthy Guangzhou, rising incomes and fear of diseases are sending well-heeled consumers to supermarkets in search of packaged and branded goods.Yet outside of China's glitzy marquee cities of Shanghai, Beijing, and Guangzhou, traditional wet markets still account for the bulk of fresh food sales in China."The concept of buying food once a week and putting it in your fridge doesn't really exist in China yet. It's produced today, bought today, and eaten later today," said John Chapple, general manager for China-based food analysis laboratory Sino Analytica.And dangerous tastes persist under the radar.Although Guangdong authorities culled thousands of civets in January 2004, investigators recently found the animals, as well as badgers and pangolins, on the black market and in Guangdong's "wild flavor" restaurants, where diners hope exotic meats will bring good fortune.Health inspectors found 14 frozen and one live civet cat, and 22 kilograms of civet cat meat from 18 animals in a sweep of restaurants across the province, the People's Daily newspaper reported earlier this year."You can't say something else won't come up," said Li Jib-heng, general specialist at the Department of Health in Taiwan.The odds of another human catching SARS from a sick civet cat were next to none, Li said, but added a new disease could emerge from close contact with sick wild animals.Keeping clear of wild animals could prove difficult for some locals, who are known for their eclectic palettes.Among Qingping's cats and chickens were tiger paws, turtles, insects of myriad varieties, and bundled strips of shredded toads -- some food, others medicine."You can eat anything with four legs except the dinner table," says one local expression.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 

 

 

 

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.